Alzheon Revenue and Competitors

USA

Location

#4086

Growjo Ranking

Estimated Revenue & Valuation

  • Alzheon's estimated annual revenue is currently $3.2M per year.(i)
  • Alzheon's estimated revenue per employee is $106,400
  • Alzheon's total funding is $128M.
  • Alzheon's current valuation is $1.3B.

Employee Data

  • Alzheon has 30 Employees.(i)
  • Alzheon grew their employee count by 30% last year.

Alzheon's People

NameTitleEmail/Phone
1
Founder, President & CEOReveal Email/Phone
2
CSOReveal Email/Phone
3
Chief StaffReveal Email/Phone
4
VP Program and Portfolio ManagementReveal Email/Phone
5
VP Clinical DevelopmentReveal Email/Phone
6
VP Clinical Development and Medical AffairsReveal Email/Phone
7
VP Brand MarketingReveal Email/Phone
8
VP Market AccessReveal Email/Phone
9
VP MarketingReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.1M1015%N/AN/A
#2
$212.8M10635%$65MN/A
#3
$1M12N/AN/AN/A
#4
$35.6M2316%N/AN/A
#5
$45M299-4%$102.6MN/A
#6
$12.3M8813%N/AN/A
#7
$2.5M26N/AN/AN/A
#8
$27.2M181-36%$162.2MN/A
#9
$0.4M11-31%$11.4MN/A
#10
$1.2M14-33%N/AN/A
Add Company

What Is Alzheon?

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com

keywords:N/A

$128M

Total Funding

30

Number of Employees

$3.2M

Revenue (est)

30%

Employee Growth %

$1.3B

Valuation

N/A

Accelerator

Alzheon News

2022-04-20 - Money on the Move: Tessera, Unlearn.AI, Blue Spark, Alzheon ...

Money on the Move: Tessera, Unlearn.AI, Blue Spark, Alzheon and Trevana. Published: Apr 20, 2022 By Hannah Chudleigh. Funding. The major pharma and biotech...

2022-04-17 - Alzheon Announces Closing of Oversubscribed $50 Million ...

Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and...

2022-04-17 - Alzheimer’s Drug Developer Alzheon Secures $50 Million

Biotechnology company Alzheon Inc. has raised $50 million in new venture capital to complete clinical trials of a potential oral medication...

2021-06-04 - Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ‑801 in Patients with Early Alzheimer's Disease

Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the dosing of the first patient in its APOLLOE4 Phase 3 study evaluating the efficacy and safe ...

2018-03-19 - Alzheon files for $80M IPO to take once-failed Alzheimer's drug in­to PhI­II

A com­pa­ny based just out­side Boston is join­ing the pa­rade to the pub­lic mar­kets, hop­ing to raise $80.5 mil­lion to de­vel­op an Alzheimer’s drug that’s a true Hail Mary, con­sid­er­ing the field’s re­cent im­plo­sions. Mar­tin To­lar The drug­mak­er, Alzheon, filed a no­tice with the S ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.9M30-9%N/A
#2
$5.9M307%N/A
#3
$5.9M300%N/A
#4
$2.4M3030%N/A
#5
$5M30-6%N/A